Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 3/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621752 | 1.00 | IRAK4 (0.55) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621762 | 0.92 | IRAK4 (0.47) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621758 | 0.86 | PDGFRB (0.61) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621748 | 0.86 | PDGFRB (0.59) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621749 | 0.84 | PDGFRB (0.45) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621761 | 0.83 | IRAK4 (0.58) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL30399892 | 0.82 | PDGFRB (0.46) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL2621741 | 0.82 | PDGFRB (0.46) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL2621745 | 0.81 | IRAK4 (0.47) | IRAK4PDGFRBPDGFRAEGFRINSR | |
| SCHEMBL2621744 | 0.79 | PDGFRB (0.43) | PDGFRBPDGFRAEGFRINSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | IRAK4 3826/4885PDGFRB 633/4885PDGFRA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.